Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CASP1 | P29466 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6404698 | 0.80 | CYP1A2 (0.37) | KDM4ECYP1A2CASP1ALDH1A1ABCB11 | |
| SCHEMBL5086460 | 0.80 | RAD52 (0.35) | KDM4ECYP1A2CASP1ALDH1A1ABCB11 | |
| SCHEMBL6269582 | 0.77 | KDM4E (0.46) | KDM4ECYP1A2CASP1ALDH1A1ABCB11 | |
| Hydrochloric Acid SCHEMBL6271964 | 0.76 | ALDH1A1 (0.46) | KDM4ECYP1A2CASP1ALDH1A1ABCB11 | |
| SCHEMBL14157668 | 0.68 | KDM4E (0.66) | KDM4ECYP1A2CASP1ALDH1A1ABCB11 | |
| SCHEMBL4727790 | 0.68 | GAA (0.35) | KDM4ECYP1A2ALDH1A1CYP3A4CYP2D6 | |
| SCHEMBL4729566 | 0.64 | NFKBIA (0.41) | KDM4ECYP1A2ALDH1A1LMNATP53 | |
| SCHEMBL4726083 | 0.63 | RAD52 (0.36) | KDM4ECYP1A2CASP1ALDH1A1ABCB11 | |
| SCHEMBL5083301 | 0.63 | POLB (0.32) | POLBGAA | |
| SCHEMBL5080647 | 0.62 | MAOA (0.66) | KDM4ECYP1A2CASP1ALDH1A1ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | CHDI, INCORPORATED | 2008-02-21 | — | — | US | disclosed |
| US-6979740-B2 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH (IN) | 2005-12-27 | — | — | US | disclosed |
| EP-1606263-A1 | RING-SUBSTITUTED 8-AMINOQUINOLINE DERIVATIVES AS ANTIMALARIAL AGENTS | Council of Scientific and Industrial Research (IN) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004085402-A1 | RING-SUBSTITUTED 8-AMINOQUNOLINE DERIVATES AS ANTIMALARIAL AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-10-07 | — | — | WO | disclosed |
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH DEPARTMENT OF PHARMACEUTICAL TECHNOLOGY (IN) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192724-A1 | Process for preparation of ring-substituted 8-aminoquinoline analogs as antimalarial agents | QDPR, SLC11A2, CYP2C8 | KDM4E 64/4885CYP1A2 66/4885CASP1 343/4885 |
| US-20080044390-A1 | Methods and compositions for the treatment of neurodegenerative disorders | HTT, SNCA, NLN | KDM4E 3242/4885CYP1A2 4587/4885CASP1 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.